3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is growing attracting clinical focus due to sparse data suggesting unique biological characteristics. Preliminary analyses indicate that 3-HPC may possess distinct impacts on the central nervous system, potentially contributing to some of the unexplained manifestations asso